Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA extended ...

A late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting showed that alectinib demonstrates efficacy and favorable tolerability compared with crizotinib in the primary ...

The drug, approved in Japan last year, had been granted Breakthrough Therapy designation by the FDA. Roche has announced that an oral anaplastic lymphoma kinase (ALK) inhibitor developed by the ...

Alectinib should not be used in patients who are allergic to the drug, patients with the history of liver or lung disease, exposure to excessive sunlight, during pregnancy or breast feeding. Alectinib ...

MADRID -- Disease-free survival (DFS) in resectable ALK-positive non-small cell lung cancer (NSCLC) improved by 76% with adjuvant alectinib (Alecensa) compared with chemotherapy, according to a ...

Review the side-effects of Alectinib as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following tumor resection in patients with anaplastic lymphoma kinase (ALK)–positive ...

Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Compared to the current standard of care ...

The National Institute for Health and Care Excellence (NICE) has recommended alectinib (Alecensa) for ALK-positive non-small cell lung cancer following surgery to reduce recurrence risk. Around 100 ...

The appraisal committee considered evidence submitted by Roche and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

First, the lung cancer study. In a Phase III clinical trial, in which patients receive either a standard or an experimental treatment at random, a new drug called alectinib (brand name, Alecensa) ...